Alzamend Neuro, Inc. requests that their press release NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type” be killed.
--(BUSINESS WIRE)-- Alzamend Neuro, Inc., requests that their press release NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type” be killed.
The release was issued in error by Alzamend Neuro, Inc.
A replacement release was issued on April 3, 2023, at 08:50 AM Eastern Time.
Source:
View this news release online at:
http://www.businesswire.com/news/home/20230403005455/en
